USANA Health Sciences, Inc. (NYSE:USNA) had its price target dropped by research analysts at Pivotal Research from $75.00 to $70.00 in a report released on Wednesday, Marketbeat reports. The brokerage currently has a “buy” rating on the stock. Pivotal Research’s target price points to a potential upside of 21.85% from the company’s current price.

Other equities research analysts have also issued reports about the company. BidaskClub upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday, June 13th. Zacks Investment Research upgraded USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, April 12th.

USANA Health Sciences (NYSE:USNA) traded down 11.27% on Wednesday, reaching $57.45. The company had a trading volume of 649,097 shares. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of 14.50 and a beta of 1.13. The company has a 50-day moving average of $64.22 and a 200 day moving average of $60.96. USANA Health Sciences has a one year low of $52.55 and a one year high of $75.00.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, July 25th. The company reported $0.98 earnings per share for the quarter, missing the consensus estimate of $1.06 by $0.08. USANA Health Sciences had a net margin of 9.71% and a return on equity of 31.84%. The company had revenue of $257.10 million during the quarter, compared to the consensus estimate of $273.61 million. During the same quarter in the prior year, the company posted $2.07 earnings per share. The company’s revenue for the quarter was down .5% on a year-over-year basis. On average, equities research analysts predict that USANA Health Sciences will post $3.95 EPS for the current year.

USANA Health Sciences announced that its board has approved a share buyback program on Tuesday, July 25th that allows the company to buyback $64.60 million in outstanding shares. This buyback authorization allows the company to repurchase up to 46% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/26/usana-health-sciences-inc-usna-given-new-70-00-price-target-at-pivotal-research.html.

In related news, insider Paul A. Jones sold 9,851 shares of the stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $64.50, for a total transaction of $635,389.50. Following the sale, the insider now directly owns 6,020 shares in the company, valued at approximately $388,290. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Myron W. Wentz sold 40,000 shares of the stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $64.99, for a total value of $2,599,600.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 134,735 shares of company stock worth $8,371,021. 53.20% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its position in shares of USANA Health Sciences by 1.2% in the first quarter. JPMorgan Chase & Co. now owns 16,044 shares of the company’s stock worth $924,000 after buying an additional 196 shares during the last quarter. Clinton Group Inc. raised its position in shares of USANA Health Sciences by 4.9% in the first quarter. Clinton Group Inc. now owns 5,238 shares of the company’s stock worth $302,000 after buying an additional 245 shares during the last quarter. American International Group Inc. raised its position in shares of USANA Health Sciences by 7.1% in the first quarter. American International Group Inc. now owns 6,392 shares of the company’s stock worth $368,000 after buying an additional 422 shares during the last quarter. Symons Capital Management Inc. raised its position in shares of USANA Health Sciences by 10.0% in the first quarter. Symons Capital Management Inc. now owns 5,490 shares of the company’s stock worth $316,000 after buying an additional 500 shares during the last quarter. Finally, Aperio Group LLC raised its position in shares of USANA Health Sciences by 11.1% in the second quarter. Aperio Group LLC now owns 11,485 shares of the company’s stock worth $736,000 after buying an additional 1,149 shares during the last quarter. Hedge funds and other institutional investors own 44.21% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.